ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF), the Canadian antibody discovery company, told investors Thursday it has tapped Andy Nixon, a senior executive with the German pharmaceutical company Boehringer Ingelheim, as a member of its board.
Nixon, a vice-president of Biotherapeutics Molecule Discovery at Boehringer Ingelheim, boasts expertise in biologic drug discovery and non-clinical development work as well.
Also on his list of career accomplishments is his leading of the research team that developed the US pharmaceutical group Dyax’s pipeline drug candidates and helped to trigger rival Shire’s acquisition of Dyax in 2016 for $5.9 billion.
READ: ImmunoPrecise and TetraGenetics extend alliance to discover therapeutic antibodies for autoimmune disease
“As ImmunoPrecise advances its strategy for accelerate growth in the custom therapeutic antibody space, and for sustainable shareholder value creation, Dr. Nixon brings a unique depth of experience and expertise that is directly relevant to ImmunoPrecise,” said Jennifer Bath, ImmunoPrecise’s CEO and president.
“We are pleased to have Dr. Nixon support ImmunoPrecise through the next phase of our development,” Bath added.
Now that Nixon has joined, ImmunoPrecise’s board will be made up of seven members.
The Victoria, British Columbia-headquartered company provides global antibody services ranging from target analysis to pre-clinical studies.
ImmunoPrecise is concentrating on discovering the most relevant next-generation antibodies that it feels has the highest probability of succeeding through clinical trials.
ImmunoPrecise shares held steady at C$0.82 in morning Canadian trade on Thursday.
Contact Ellen Kelleher at [email protected]